Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Papp

Showing results (71-80 of 137) with videos related to

Pageof 14
Sort By:
Arthritis and Rheumatism|July 19, 2012
Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled studyGeorg Schett, Jurgen Wollenhaupt, Kim Papp, et al.
Journal of the American Academy of Dermatology|January 14, 2015
WITHDRAWN: Experience with ustekinumab in patients with psoriasis enrolled in a large, multicenter, prospective, disease-based registry (Psoriasis Longitudinal Assessment and Registry [PSOLAR])Kim Papp, Alice B Gottlieb, Luigi Naldi, et al.
Journal of the American Academy of Dermatology|February 21, 2006
A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasisRobert Bissonnette, Kim Papp, Yves Poulin, et al.
Lancet (London, England)|October 18, 2005
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trialKristian Reich, Frank O Nestle, Kim Papp, et al.
Journal of Drugs in Dermatology : JDD|July 8, 2015
Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Kim Papp, Alice B Gottlieb, Luigi Naldi, et al.
Journal of Drugs in Dermatology : JDD|January 28, 2020
Topical Agents for the Treatment of Atopic DermatitisLawrence F. Eichenfield, Thomas Luger, Kim Papp, et al.
Journal of Cutaneous Medicine and Surgery|February 12, 2019
Treating to Target(s) With Interleukin-17 InhibitorsCharles W Lynde, Jennifer Beecker, Jan Dutz, et al.
Acta Dermato-Venereologica|February 16, 2022
Time to Loss of Response following Withdrawal of Ixekizumab in Patients with Moderate-to-Severe PsoriasisKim Papp, Carle Paul, C Elise Kleyn, et al.
Archives of Dermatology|December 22, 2010
Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trialCraig Leonardi, Richard G Langley, Kim Papp, et al.
Journal of the American Academy of Dermatology|November 14, 2006
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasisAlan Menter, Steven R Feldman, Gerald D Weinstein, et al.
Pageof 14

Showing results (71-80 of 137) with videos related to

Sort By:
Pageof 14
Arthritis and Rheumatism|July 19, 2012
Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled studyGeorg Schett, Jurgen Wollenhaupt, Kim Papp, et al.
Journal of the American Academy of Dermatology|January 14, 2015
WITHDRAWN: Experience with ustekinumab in patients with psoriasis enrolled in a large, multicenter, prospective, disease-based registry (Psoriasis Longitudinal Assessment and Registry [PSOLAR])Kim Papp, Alice B Gottlieb, Luigi Naldi, et al.
Journal of the American Academy of Dermatology|February 21, 2006
A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasisRobert Bissonnette, Kim Papp, Yves Poulin, et al.
Lancet (London, England)|October 18, 2005
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trialKristian Reich, Frank O Nestle, Kim Papp, et al.
Journal of Drugs in Dermatology : JDD|July 8, 2015
Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Kim Papp, Alice B Gottlieb, Luigi Naldi, et al.
Journal of Drugs in Dermatology : JDD|January 28, 2020
Topical Agents for the Treatment of Atopic DermatitisLawrence F. Eichenfield, Thomas Luger, Kim Papp, et al.
Journal of Cutaneous Medicine and Surgery|February 12, 2019
Treating to Target(s) With Interleukin-17 InhibitorsCharles W Lynde, Jennifer Beecker, Jan Dutz, et al.
Acta Dermato-Venereologica|February 16, 2022
Time to Loss of Response following Withdrawal of Ixekizumab in Patients with Moderate-to-Severe PsoriasisKim Papp, Carle Paul, C Elise Kleyn, et al.
Archives of Dermatology|December 22, 2010
Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trialCraig Leonardi, Richard G Langley, Kim Papp, et al.
Journal of the American Academy of Dermatology|November 14, 2006
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasisAlan Menter, Steven R Feldman, Gerald D Weinstein, et al.
Pageof 14